4th Quarter - Report — NATIONAL ORGANIZATION FOR RARE DISORDER… for NATIONAL ORGANIZATION FOR RARE DISORDER… (2015)

Firm

NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)

Client

NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD)

Income

—

Expenses

—

No amount is shown when the filer reports less than $5,000 for the period, which the form does not ask them to state.

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

H.R. 6 - The 21st Century Cures Act Orphan Drug Tax Credit H.R. 1537/S. 1878 - Advancing Hope Act of 2015 H.R. 209/S. 139 - Ensuring Access to Clinical Trials Act S. 2188 - Rare Disease Innovation Act H.R. 3731 - RAD Fund Act H.R. 3678 - Preserving Access to Orphan Drug Act S. 2030 - Advancing Targeted Therapies for Rare Diseases Act H.R. 2624 - Part D Beneficiaries Appeals Fairness Act S. 1421 - OPEN Act

Lobbyist	Covered position, as disclosed
PAUL MELMEYER	—
MARTHA L RINKER New	Vice President of Public Policy

Contacted: Food & Drug Administration (FDA); Social Security Administration (SSA); HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 2188 (114th), H.R. 1537 (114th), S. 139 (114th), S. 2030 (114th), H.R. 3731 (114th), H.R. 6 (114th), H.R. 2624 (114th), S. 1878 (114th), H.R. 209 (114th), H.R. 3678 (114th), S. 1421 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.